SLDB:NASDAQSolid Biosciences Inc. Analysis
Data as of 2026-05-27 - not real-time
$7.02
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Solid Biosciences (SLDB) is trading near its 20‑day simple moving average (7.02 vs 7.03) with a neutral RSI (48.4) and a bearish MACD histogram (‑0.02), suggesting short‑term price pressure is modest yet the market sentiment is unusually optimistic, reflected by an “Extreme Greed” fear‑greed index of 92.34.
Fundamentally the company shows no revenue, negative earnings (‑1.92 trailing EPS) and sizable cash burn (‑$110.9 M free cash flow), a stark contrast to its solid cash balance ($380.7 M) and a low debt‑to‑equity ratio (5.5) that keeps the balance sheet solvent, while the price‑to‑book multiple (1.85) sits well below the industry PE average (27.4), indicating the stock may be undervalued relative to its assets.
The biotech sector adds considerable regulatory risk – multiple early‑stage trials (Phase 1/2 SGT‑003, Phase 3 IMPACT Duchenne) are still pending approval – and the high beta (2.32) and 30‑day volatility (64 %) amplify that risk, leading to an overall risk score of 7/10, medium liquidity risk, and a recommendation to hold in the short term, buy on a medium‑term basis, and maintain a hold stance for the long term.
Fundamentally the company shows no revenue, negative earnings (‑1.92 trailing EPS) and sizable cash burn (‑$110.9 M free cash flow), a stark contrast to its solid cash balance ($380.7 M) and a low debt‑to‑equity ratio (5.5) that keeps the balance sheet solvent, while the price‑to‑book multiple (1.85) sits well below the industry PE average (27.4), indicating the stock may be undervalued relative to its assets.
The biotech sector adds considerable regulatory risk – multiple early‑stage trials (Phase 1/2 SGT‑003, Phase 3 IMPACT Duchenne) are still pending approval – and the high beta (2.32) and 30‑day volatility (64 %) amplify that risk, leading to an overall risk score of 7/10, medium liquidity risk, and a recommendation to hold in the short term, buy on a medium‑term basis, and maintain a hold stance for the long term.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- bearish MACD histogram indicating limited upside momentum
- neutral RSI and price near SMA20 suggesting price stability
- high beta and volatility increasing short‑term risk
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- ongoing Phase 3 IMPACT Duchenne trial and positive EMA pediatric plan opinion
- significant cash on hand relative to market cap
- undervalued price‑to‑book ratio compared with industry peers
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- persistent regulatory and clinical development risk in biotech
- absence of revenue and negative earnings limiting intrinsic value
- solid balance sheet but limited dividend sustainability
Key Metrics & Analysis
Financial Health
P/E Ratio-3.6
ROE-57.37%
ROA-32.03%
Debt/Equity5.52
P/B Ratio1.8
Op. Cash Flow$-171668992
Free Cash Flow$-110968752
Industry P/E27.4
Technical Analysis
TrendNeutral
RSI48.4
Support$6.00
Resistance$7.93
MA 20$7.03
MA 50$7.43
MA 200$6.18
MACDBearish
VolumeStable
Fear & Greed Index92.34
Valuation
Target Price$17.00
Upside/Downside142.17%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta2.32
Volatility64.21%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.